Investors Purchase Large Volume of Alphatec Put Options (NASDAQ:ATEC)

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Traders acquired 4,816 put options on the company. This is an increase of 246% compared to the average daily volume of 1,392 put options.

Alphatec Stock Up 3.2 %

NASDAQ ATEC traded up $0.33 during midday trading on Friday, hitting $10.56. 2,292,621 shares of the company traded hands, compared to its average volume of 2,044,289. Alphatec has a 52 week low of $4.88 and a 52 week high of $13.79. The company's 50-day simple moving average is $10.37 and its 200-day simple moving average is $9.48. The company has a market cap of $1.52 billion, a PE ratio of -8.25 and a beta of 1.20. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. As a group, equities research analysts forecast that Alphatec will post -1.08 earnings per share for the current year.

Insider Activity at Alphatec

In other Alphatec news, CEO Patrick Miles sold 50,000 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total transaction of $601,500.00. Following the sale, the chief executive officer now directly owns 6,152,544 shares of the company's stock, valued at $74,015,104.32. The trade was a 0.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP David Sponsel sold 36,256 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $11.42, for a total value of $414,043.52. Following the completion of the sale, the executive vice president now directly owns 735,074 shares of the company's stock, valued at $8,394,545.08. The trade was a 4.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 278,800 shares of company stock valued at $3,201,469. 22.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd acquired a new position in shares of Alphatec during the fourth quarter valued at about $29,000. Comerica Bank lifted its stake in shares of Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after buying an additional 1,248 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock valued at $43,000 after acquiring an additional 4,234 shares during the period. Quarry LP raised its stake in Alphatec by 79.2% in the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after acquiring an additional 2,375 shares during the last quarter. Finally, Newton One Investments LLC purchased a new stake in Alphatec during the 4th quarter valued at about $50,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on ATEC shares. Needham & Company LLC reiterated a "buy" rating and set a $16.00 price target on shares of Alphatec in a report on Thursday, February 27th. Barclays raised their price target on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 22nd. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Monday, April 14th. StockNews.com raised shares of Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Finally, Piper Sandler raised their price target on shares of Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.67.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.